Signal · Supply Chain & Logistics
Samsung Biologics to raise W3tr in rights issue for peptide maker deal
What the source reported
Source-reportedSamsung Biologics is planning to raise over 3 trillion won ($2.2 billion) through a share offering to fund its acquisition of a peptide manufacturer and a new production campus, as competition among global drugmakers intensifies. In a regulatory filing Friday, Samsung Biologics said its board approved the offering, issuing 2.27 million new shares at 1,322,000 won apiece, a 15 percent discount that will expand its share count by 4.9 percent. Of the proceeds, 2.71 trillion won will fund the acquis
- Publication
- The Korea Herald - Business · Business News
- Published
- 28th August 2026
- Original report
- koreaherald.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- South Korea
- Organisations
- None identified
- Collected
- 28th August 2026 · 04:55
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Moderate (36.0/100). Strongest contributor: Entity Criticality (20.0/20 points). Limiting factor: Likely Event Severity (3.0/30 points). Initial Confidence Low (23.5/100, data sufficiency: Partial). Strongest contributor: Source Authority (12.0/40 points). Limiting factor: Corroboration (2.5/25 points).
- Strongest contributor
- Entity Criticality
- Limiting factor
- Likely Event Severity